Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Derma Sciences Inc (NASDAQ: DSCI) acted responsibly on behalf of investors’ profitability in the planned $204 million sale to Integra LifeSciences Holdings Corporation (NASDAQ: IART).

On January 10, 2017, Derma Sciences Inc (NASDAQ: DSCI) and Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced that they had entered into a merger agreement. Under the terms of the merger agreement, Derma Sciences common shareholders will receive $7 per share, while holders of Series A Convertible Preferred Stock will receive $32 per share, and holders of Series B Convertible Preferred Stock will receive $48 per share.

Based in Princeton, New Jersey, and founded in 1984 Derma Sciences Inc operates as a medical device company in the wound care market.

The investigation focuses on whether NASDAQ: DSCI investors received the highest price and whether the directors of Derma Sciences Inc acted in the best interest of Derma Sciences Inc company and its shareholders. 

If you purchased Derma Sciences Inc (NASDAQ: DSCI) prior to January 10, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185